A unit of Johnson & Johnson, just months after saying it was phasing out an artificial hip implant because of slowing sales, has warned doctors that the device appears to have a high early failure rate in some patients.
On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.
It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards.
This morning, BMO Capital Markets biotech analyst Jason Zhang downgraded shares of Amylin Pharmaceuticals to the equivalent of "Sell."
President Obama has high cholesterol. For now, his doctors are prescribing healthy living. But some say he should be put on a statin or cholesterol-lowering drug pronto.
Shares of Dendreon fell around 10 percent before the market opened. And now, in regular trading, they're at a new intra-day high. Here's what happened.
When a major pharma company holds analyst/investor meetings as infrequently as Bristol-Myers Squibb, it's kind of a must-cover event.
The Food and Drug Administration says its decisions are always based on the science. But on rare occasions ol' mother nature apparently can get in the way.
On day five of Avandiagate, GlaxoSmithKline communiques about the brouhaha surrounding the controversial diabetes drug now number six.
The company is suing more than half a dozen generic drug firms that want to make a cheaper copy of Crestor years before the patent on the drug is set to expire. But you won't find me sitting in the pews furiously taking notes.
I suppose it’s possible President Obama could have come up with a more anti-market reform to deal with its concerns over higher health insurance rates, but short of creating a single-payer health system, creating a seven-member panel to dictate the prices of health insurance is pretty close.
Big pharmaceutical companies have been raising prices on a lot of drugs recently. Some critics say the industry's trying to cash in before government price controls possibly get put into place.
As someone who studies the way people perceive risk, and the importance of trust to those perceptions, it continues to amaze me how many smart successful firms like Toyota manage to forget the importance of trust until they’re in trouble, and then they have to spend huge amounts of money and effort, for years, trying to rebuild it, writes the author David Ropeik.
A source tells CNBC that former President Bill Clinton received two drug-coated stents, called "Xience," made by Abbott Labs.
Washington’s new political reality has left the fate of comprehensive healthcare reform uncertain, but there’s still plenty Congress and the Obama administration can do to improve the American healthcare system, writes this CEO.
Lockstep with Boomer aging, established industries are about to grow exponentially, and new wealth will be created by enterprises yet to be conceived.
Suffice to say that diabetes is a huge and fast-growing problem and represents a huge and fast-growing drug and device market.
I’m kind of torn over the fact that I’ve decided I won’t be going to the annual American College of Cardiology meeting in Atlanta about a month from now.
If you're left-handed, bowl with your right, eat red licorice, but only on Sunday afternoons, are female under 24-and-a-half years old or male over 33-and-three-quarters and loved "Dances With Wolves," then our drug is now approved for you to take.
I don't buy into the silly conspiracy theories that global health authorities worked in cahoots with the big, bad drug companies to gin up a pandemic scare just to goose vaccine and flu drug sales. Try telling that to the family of someone who died from H1N1.